Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494025 | 0.86 | SIGMAR1 (0.40) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL25429497 | 0.82 | OPRL1 (0.41) | SIGMAR1OPRL1 | |
| SCHEMBL8330793 | 0.81 | NUDT1 (0.52) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL11632591 | 0.81 | SIGMAR1 (0.43) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL11675755 | 0.79 | NUDT1 (0.45) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL11633835 | 0.78 | SIGMAR1 (0.46) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL11799765 | 0.78 | NUDT1 (0.44) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL27520139 | 0.78 | NUDT1 (0.44) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| SCHEMBL11674401 | 0.78 | BACE1 (0.48) | SIGMAR1NUDT1BACE1TMEM97EBP | |
| Hydrochloric Acid SCHEMBL30343200 | 0.77 | SIGMAR1 (0.45) | SIGMAR1NUDT1BACE1TMEM97EBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0917464-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1999-05-26 | — | — | EP | claimed |
| WO-1998004251-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1998-02-05 | — | — | WO | claimed |
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS THERAPEUTICS (FR) | 2023-11-16 | — | — | US | disclosed |
| EP-4213822-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | MELETIOS Therapeutics (FR) | 2023-07-26 | — | — | EP | disclosed |
| EP-0917464-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998004251-A1 | USE OF AMINES TO PRODUCE DRUGS FOR PREVENTING TUMOUR CELL PROLIFERATION | SANOFI (FR) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364033-A1 | COMPOUNDS FOR TREATING VIRUS INFECTIONS | ACE, HAVCR2, FURIN | SIGMAR1 3429/4885NUDT1 379/4885BACE1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.